Market Analysis
Why Kenvue Stock Is Down in Premarket Today: Trump Team Targets Tylenol–Autism Link
KVUE shares declined 6% premarket amid reports linking Tylenol to autism risks.
BTC$62,533.00-3.27%
ETH$1,660.02-4.47%
USDT$0.9988-0.01%
USDC$0.9998+0.00%
XRP$1.10-3.16%
SOL$68.97-5.07%
TRX$0.3301-0.45%
FIGR_HELOC$1.04+0.35%
HYPE$62.57-7.36%
DOGE$0.079-5.01%
USDS$0.99960.00%
RAIN$0.0157+4.11%
LEO$9.54-0.17%
ZEC$417.90-7.62%
XLM$0.1932-6.36%
BTC$62,533.00-3.27%
ETH$1,660.02-4.47%
USDT$0.9988-0.01%
USDC$0.9998+0.00%
XRP$1.10-3.16%
SOL$68.97-5.07%
TRX$0.3301-0.45%
FIGR_HELOC$1.04+0.35%
HYPE$62.57-7.36%
DOGE$0.079-5.01%
USDS$0.99960.00%
RAIN$0.0157+4.11%
LEO$9.54-0.17%
ZEC$417.90-7.62%
XLM$0.1932-6.36%
Kenvue shares surged 18% after Kimberly-Clark revealed a $48.7 billion buyout, forming one of the largest U.S. consumer health companies.
KVUE shares declined 6% premarket amid reports linking Tylenol to autism risks.
Activist hedge fund Starboard Value has reportedly taken a stake in Kenvue, sparking a pre-market stock surge.